February 17: The Week in Cancer News
More older women with breast cancer may not need radiation therapy, and more news from the week, selected by the editors of Cancer Today.
Progress Against Cancer
More older women with breast cancer may not need radiation therapy, and more news from the week, selected by the editors of Cancer Today.
Patients with lung cancer who received an immune checkpoint inhibitor before surgery had improved long-term survival rates and lower rates of recurrence than historically observed, according to a study published in an AACR journal....
A drug that selectively targets cancer cells was approved for the treatment of certain HR-positive breast cancers. The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy) for patients with locally advanced...
Patients who receive certain forms of chemo face long-term risk for heart failure, and screening levels for certain cancers remain below expectations.
Guest Post by William G. Nelson, MD, PhD, Editor-in-Chief, Cancer Today Many argue that warfare metaphors, with winners and losers, may not be the best way to imagine the entirety of the cancer experience. With that...
The FDA approved the immune checkpoint inhibitor dostarlimab-gxly to treat advanced uterine cancer with certain mutations. The U.S. Food and Drug Administration (FDA) has approved dostarlimab-gxly (Jemperli) for the treatment of adult patients with...
Immunotherapy before surgery is proving to be an effective treatment against melanoma.
Group says more women should consider removing fallopian tubes to lower ovarian cancer risk, and more stories selected by the editors of Cancer Today.
The FDA has approved the oral SERD elacestrant to treat certain patients with estrogen receptor-positive breast cancer. The U.S. Food and Drug Administration (FDA) has approved elacestrant (Orserdu) for the treatment of men and...
The FDA granted accelerated approval to the BTK inhibitor pirtobrutinib for the treatment of mantle cell lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca) for the treatment...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More